Much of the historical progress has been led by AI-native drug discovery companies that offer software or service to pharma players. And facilitating such services by one-of-a-kind organic chemists having expertise in molecular modeling combined with the knowledge of AI can only bring about disruption. So is this inspiring interview with Hanjo Kim, SVP of Global Strategy, Head of Medicinal Chemistry at Standigm. 

He believes that AI has the potential to propagate to other intersections of different expertise and improve the overall productivity in drug discovery. To learn more kindly go through the interview highlights below:

Please brief our audience about yourself and your role as the SVP of Global Strategy, Head of Medicinal Chemistry at Standigm.

I’m an organic chemist by training and education. I have worked for various organizations, a non-profit research organization, a biotech, and a pharmaceutical company, before joining Standigm in 2019. I led the development of Standigm BEST, its chemistry technology, until 2021. From 2022, my role has changed to half research, head of medicinal chemistry, and the other half business development.

Please share your source of inspiration for exploring various facets of technology.

As an organic chemist with molecular modeling expertise, I have spent my entire professional career living on the edge of two totally different disciplines; wet lab and dry lab. As these two have different philosophies, customs, and ways of thinking, my primary job has been as a translator or a facilitator in most cases. Therefore, it was natural for me to join Standigm and deal with combining AI and drug discovery, two different technologies. The questions from experts with diverse backgrounds are a trustworthy source of inspiration.

Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!